TECHNOLOGY LICENSING OPPORTUNITY: DC Recruiter
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Energy's Los Alamos National Laboratory (LANL) is offering a technology licensing opportunity for "DC Recruiter," a novel broad-spectrum immune enhancer. This Special Notice seeks partners for exclusive or non-exclusive licensing agreements for this patented/patent-pending invention. Responses are due by December 16, 2026.
Scope of Opportunity
DC Recruiter is a self-assembling peptide nanofiber designed to recruit and activate dendritic cells (DCs), the immune system's natural sentinels. This technology offers a differentiated approach to multi-pathogen infection prevention by stimulating an early immune response regardless of the infecting agent, unlike pathogen-specific vaccines or therapeutics. It is designed to be needle-free and spray-friendly, enhancing practicality.
Key Advantages:
- Helps the body respond faster after exposure to an infection.
- Works in a broad, pathogen-agnostic way.
- Targets dendritic cells to alert and activate the immune system.
- May be useful when the exact cause of infection is unknown.
- Could be helpful in outbreak, emergency, or high-risk settings.
- Potential for easier use as a needle-free spray.
Development Status: Technology Readiness Level (TRL) 3, with a U.S. Patent pending.
Market Applications
- Infectious Disease Prevention (early-response immune support, broad-spectrum protection)
- Outbreak Response and Public Health (rapid deployment, exposure mitigation)
- Defense and National Security (force protection, biological threat preparedness)
- Consumer Health and Wellness (easy-to-use immune support, potential spray format)
- Pharmaceuticals and Biotech (next-generation immunomodulation, platform development)
- Emergency Preparedness (first-response tools, high-risk exposure settings)
Licensing & Timeline
LANL's licensing program aims to move inventions to commercial innovations through exclusive and non-exclusive licensing agreements. Interested companies should contact LANL for specific discussions.
- Response Due: December 16, 2026
- Published: June 15, 2026
- Contact: Caleb Ledgerwood or Lindsay Augustyn at
licensing@lanl.gov
Additional Notes
This is not a call for external services for the development of this technology; it is solely for technology licensing.